More research is being conducted to assess the combination of ipilimumab and nivolumab, as well as durvalumab and tremelimumab (an additional CTLA-4 inhibitor), in HER2-positive breast cancer patients [41]. The gene discussed is ERBB2; the disease is breast carcinoma.